Background: Buprenorphine dependence is a relatively novel addiction.
Aims: To compare the treatment outcome in three groups over 12-weeks of treatment.
Methods: Two hundred and four intravenous (i.v.)-buprenorphine-dependent patients were randomised into three groups. Subjects received 50 mg oral methadone tablet, or 5 mg sublingual buprenorphine tablet, or 50 mg oral naltrexone, and a weekly 30-minute clinical counselling session.
Results: The majority (80%) had a history of opium or heroin dependency before they were introduced to i.v. buprenorphine. The main source of buprenorphine for misusers was street sale (91%). The mean duration of buprenorphine dependence was 1.9 years and the mean dose per day was 3.9 ampoules (1 ampoule contains 0.3 mg of buprenorphine in 1 ml). Overall 59% of the patients completed the 12-week study. Retention in the 50 mg methadone group was significantly better than the 5 mg dose buprenorphine group (p=0.001) and the 50 mg dose naltrexone group (p=0.000). Retention in the 5 mg buprenorphine group was significantly better than the 50 mg naltrexone dose group (p=0.000).
Conclusions: These results support the efficacy and safety of oral methadone and sublingual buprenorphine tablets for injection buprenorphine-dependent patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/BF02915283 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Perinatal exposure to methadone or buprenorphine impairs hippocampal-dependent cognition and brain development in juvenile rats.
Prog Neuropsychopharmacol Biol Psychiatry
January 2025
School of Psychology, University of New South Wales, Sydney, Australia. Electronic address:
The opioid crisis continues to escalate, disproportionately affecting women of reproductive age. Traditionally the first line of treatment for pregnant women with opioid use disorder is the mu-opioid receptor agonist methadone. However, in recent years, the use of buprenorphine as a replacement therapy has increased as it has fewer side-effects and longer duration of action.
View Article and Find Full Text PDFManaging Dual Dependencies: A Case Study of Concurrent Low-Dose Buprenorphine Induction and Rapid Phenobarbital Taper.
J Psychoactive Drugs
January 2025
McGaw Medical Center, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Co-occurring substance use disorders are common in medical settings, yet limited literature exists on concomitant pharmacological management. We present a case where low-dose buprenorphine induction (LDBI) and rapid phenobarbital taper were performed concurrently in a hospital setting to manage co-occurring opioid dependence (on chronic methadone maintenance therapy) and benzodiazepine dependence (prescribed alprazolam). The simultaneous management was well-tolerated and completed with minimal complications, successfully enabling candidacy for the patient's preferred disposition.
View Article and Find Full Text PDFPharmacological Strategies to Decrease Long-Term Prescription Opioid Use: A Systematic Review.
J Clin Med
December 2024
Department of Pharmacy, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands.
: As long-term prescription opioid use is associated with increased morbidity and mortality, timely dose reduction of prescription opioids should be considered. However, most research has been conducted on patients using heroin. Given the differences between prescription and illicit opioid use, the aim of this review was to provide an overview of pharmacological strategies to reduce prescription opioid use or improve clinical outcomes for people who experience long-term prescription opioid use, including those with opioid use disorder.
View Article and Find Full Text PDFInsurmountable antagonism of human mu opioid receptors by buprenorphine is due to hemi-equilibrium.
Eur J Pharmacol
January 2025
Department of Pharmacology, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA, United States. Electronic address:
Buprenorphine is an FDA approved drug for the treatment of opioid use disorder and is a long-lasting, low efficacy (partial) agonist of the μ opioid receptor. As a partial agonist, buprenorphine can act as either an agonist or an antagonist depending on the efficiency of the cellular signaling system. Here we investigated the antagonist properties of buprenorphine using a genetically-encoded biosensor to monitor cAMP levels in real time in HEK293 cells expressing a relatively low density of the human μ receptor.
View Article and Find Full Text PDFCase Report: Buprenorphine for Palliation in a Patient with End Stage Renal Disease.
J Pain Palliat Care Pharmacother
December 2024
Department of Primary Care Pain Management, Bay Pines Veterans Health System, Bay Pines, Florida, USA.
End stage renal disease (ESRD) is known to be associated with pain, malaise and decreased quality of life. Pain management in the setting of dialysis is particularly challenging from a pharmacologic standpoint given altered pharmacokinetics of pain medications. Buprenorphine, a partial mu opioid receptor agonist, demonstrates superior safety profile compared to full mu opioid receptor agonists.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!